Metformin’s Potential Impact on COVID-19 Outcomes for Type 2 Diabetes Patients
Introduction
The global spread of the SARS-CoV-2 pandemic has generated valuable real-world evidence, allowing researchers to analyze vast amounts of data related to COVID-19. A new study published in The Lancet explores a potential intervention that may improve outcomes for patients with type 2 diabetes or obesity: metformin.
Study Overview
This study investigates whether metformin can protect individuals with type 2 diabetes or obesity from severe COVID-19 outcomes. It involved a retrospective analysis of an insurance claims database, examining data from January 1 to June 7, 2020. The analysis focused on patients who were hospitalized due to COVID-19 and had a diagnosis of either type 2 diabetes or obesity. Patients under 18 years of age and those with type 1 diabetes were excluded from the study.
Methodology
Participants were classified as metformin users if they had claims for at least 90 days’ worth of the medication within the 12 months preceding their COVID-19 diagnosis. The study’s primary outcome measure was in-hospital mortality. Researchers conducted regression analyses to compare outcomes between metformin users and non-users while controlling for various relevant variables to isolate the effect of metformin.
Study Findings
A total of 6,256 individuals were included in the analysis, with 2,333 in the metformin group and 3,923 in the non-metformin group. Mortality rates were higher among non-metformin users, with 20.2% of these patients dying during their hospital admission, compared to 16.9% in the metformin group. Despite these findings, the regression analysis indicated that metformin use did not significantly reduce mortality in the overall cohort. However, a subgroup analysis revealed that women who used metformin experienced significantly reduced mortality (odds ratio=0.79), with consistent results across various models and sensitivity analyses.
Mechanisms of Action
The study also discusses potential mechanisms behind metformin’s benefits. Both obesity and type 2 diabetes are linked to chronic inflammation, which may worsen COVID-19 outcomes. Metformin has been shown to lower levels of the inflammatory mediator TNF-α, with a more pronounced effect observed in women. This may explain the greater protective benefit of metformin seen in female patients.
Limitations and Future Research
While the study establishes an association between metformin use and improved outcomes, it does not conclusively demonstrate that metformin directly protects against severe COVID-19. Additionally, it does not account for variations in metformin dosage or patient adherence. The classification of metformin users based on 90 days of claims over a 12-month period may not be the most accurate. Further research is essential to determine if metformin is indeed the cause of the observed improved outcomes and to explore whether its protective effects are dose-related and specific to women.
Conclusion
This study highlights the potential of metformin as a beneficial intervention for patients with type 2 diabetes or obesity affected by COVID-19. However, more studies are needed to validate these findings and understand the underlying mechanisms better.
Written by Michael McCarthy
1. Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Metformin and risk of mortality in patients hospitalized with COVID-19: a retrospective cohort analysis. The Lancet Healthy Longevity.
Image by Monoar Rahman Rony from Pixabay